Rescue Medications

DRUG11 trials

Conditions

Bladder CancerCervical CancerEndometrial CancerEsophageal CancerEsophageal NeoplasmsGastroesophageal AdenocarcinomaGastroesophageal CancerGastroesophageal Junction

Phase 1

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

RecruitingNCT06445972

Merck Sharp & Dohme LLCEsophageal Cancer, Esophageal Neoplasms, Gastroesophageal Adenocarcinoma +1

Start: 2024-08-07End: 2030-08-08Target: 210Updated: 2026-09-03

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

CompletedNCT06460961

Merck Sharp & Dohme LLCNeoplasm Metastasis

Start: 2024-07-14End: 2026-07-29Updated: 2026-08-28

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

RecruitingNCT07227597

Merck Sharp & Dohme LLCSmall Cell Lung Cancer Extensive Stage

Start: 2026-01-29End: 2030-12-30Target: 170Updated: 2026-10-20

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

RecruitingNCT07286149

Merck Sharp & Dohme LLCLung Neoplasm Malignant

Start: 2026-04-30End: 2032-04-13Target: 140Updated: 2026-10-01

Phase 2

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

RecruitingNCT06780098

Merck Sharp & Dohme LLCLung Neoplasm

Start: 2025-05-28End: 2032-03-02Target: 144Updated: 2026-10-07

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

RecruitingNCT06979596

Merck Sharp & Dohme LLCMalignant Neoplasm

Start: 2025-08-11End: 2027-11-04Target: 250Updated: 2026-10-06

Phase 3

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Active, not recruitingNCT06132958

Merck Sharp & Dohme LLCEndometrial Cancer

Start: 2023-12-06End: 2028-01-10Target: 710Updated: 2026-08-28

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruitingNCT06356311

Merck Sharp & Dohme LLCGastroesophageal Cancer

Start: 2024-05-03End: 2027-05-06Updated: 2026-10-22

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

RecruitingNCT07216703

Merck Sharp & Dohme LLCCervical Cancer

Start: 2026-01-19End: 2031-10-29Target: 1023Updated: 2026-10-29

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

RecruitingNCT07318558

Merck Sharp & Dohme LLCOvarian Cancer, Ovarian Neoplasms

Start: 2026-02-16End: 2033-02-25Target: 900Updated: 2026-10-13

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

Not yet recruitingNCT07829783

Merck Sharp & Dohme LLCBladder Cancer

Start: 2026-10-20End: 2036-09-25Target: 400Updated: 2026-09-21

Related Papers

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

2026-10-26

TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.

Journal of Clinical Oncology2026-05-28

Study design of OMAHA-015: A phase 2 basket study of steroidogenesis inhibitor opevesostat in participants with selected solid tumors.